Search DYAI
DYADIC INTERNATIONAL INC
Nasdaq · CIK 1213809
Last close0.46
Daily change+0.03 (6.98%)
10 Years gain-69.74%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
DYAI · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
39.2Momentum
100.0Acceleration
100.0Confidence
71.0Annual Revenue9
Quarterly Revenue26
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth8.4 / 25
Quality10.9 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators5.0 / 5
Signals
Operating leverageOperating margin improved by 26.412 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Heavy share dilution · HIGHDiluted share count increased 21.9229%.
High SBC · MEDIUMStock based compensation is high relative to revenue or FCF.
Key Metrics
Revenue Growth TTM36.85%OK
Revenue CAGR 3Y1.79%OK
Gross Margin18.79%OK
Operating Margin-181.08%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y445.57%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y21.92%OK
SBC / Revenue18.95%OK
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $3.09M | $770,485.00 | -$7.19M | -$5.70M | n/a | 24.93% | -232.75% | n/a | n/a | 32.62M |
| 2025 FY Dec 31, 2024 | $3.50M | $2.30M | -$5.90M | -$3.97M | n/a | 65.82% | -168.82% | n/a | n/a | 29.32M |
| 2024 FY Dec 31, 2023 | $2.90M | $922,957.00 | -$8.23M | -$6.73M | n/a | 31.84% | -283.9% | n/a | -279.21% | n/a |
| 2023 FY Dec 31, 2022 | $2.93M | $807,110.00 | -$10.17M | -$8.08M | n/a | 27.54% | -346.92% | n/a | -202.41% | n/a |
| 2022 FY Dec 31, 2021 | $2.40M | $459,393.00 | -$14.73M | -$11.28M | n/a | 19.11% | -612.67% | n/a | -222.64% | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $4.20M | sum latest 4 fiscal quarters Revenue | OK | 0001493152-26-037258, 0001493152-25-021908 |
| Revenue Growth TTM | 36.85% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001493152-26-037258, 0001493152-25-021908 |
| Revenue CAGR 3Y | 1.79% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-012672 |
| Revenue CAGR 5Y | 14.04% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001493152-26-012672 |
| Gross Profit CAGR 3Y | -1.54% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-012672 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001493152-26-037258, 0001493152-25-021908 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 18.79% | Gross Profit / Revenue | OK | 0001493152-26-037258, 0001493152-25-021908 |
| Operating Margin | -181.08% | Operating Income / Revenue | OK | 0001493152-26-037258, 0001493152-25-021908 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001493152-26-037258 |
| Current Ratio | 1.65x | Current Assets / Current Liabilities | OK | derived |
| SBC / Revenue | 18.95% | SBC / Revenue | OK | 0001493152-26-037258, 0001493152-25-021908 |
| Revenue per Diluted Share | $0.12 | Revenue / Diluted Shares | OK | 0001493152-26-037258, 0001493152-25-021908 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | 0001493152-26-037258, 0001493152-25-021908 |